Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana CEO boosts stake with open-market share purchase
10:21am, Monday, 15'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its Chief Executive Officer Ivor Elrifi has bought 163,400 shares of the biotechnology company’s common stock...
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
07:30am, Monday, 15'th Dec 2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences withdraws proposed share offering
05:34am, Monday, 15'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has withdrawn its proposed public offering of common shares, citing market conditions. The company, focused on...
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week
03:31pm, Friday, 12'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in early Alzheim
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial
02:10pm, Friday, 12'th Dec 2025
BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week
10:27am, Friday, 12'th Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial...
Vulcan secures €2.2BN to fully fund Phase One Lionheart project
07:01am, Wednesday, 03'rd Dec 2025
Vulcan Energy Resources Ltd (ASX:VUL, OTC:VULNF, XETRA:VUL) has secured a €2.2 billion (about A$3.9 billion) financing package to fully fund Phase One of...
Tiziana Life Sciences plans spinout of IL-6 antibody program
09:09am, Tuesday, 02'nd Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed public company. Tiziana said its decision follo
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
07:00am, Tuesday, 02'nd Dec 2025
BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies,
Tiziana Life Sciences plans spinout of IL-6 antibody program
04:07am, Tuesday, 02'nd Dec 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed...
Nasdaq, Dow gain with Dell and Autodesk boosting tech
06:12am, Wednesday, 26'th Nov 2025
11:10am: Jobless claims fall Initial US jobless claims fell by 6,000 to 216,000 for the week ending November 22, the lowest level since mid-April and well...
Versarien collapses after buyer walks away, leaving company weighing administration
04:33am, Wednesday, 26'th Nov 2025
Versarien PLC (AIM:VRS, OTC:VRSRF) shares sank 38% to 0.006p, valuing the troubled engineering materials group at about £330,000, after the company said a...
Tiziana Life Sciences' Phase 2 foralumab trial joins Healey ALS MyMatch Program
09:24am, Tuesday, 25'th Nov 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS My
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
08:30am, Tuesday, 25'th Nov 2025
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, t
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program
04:19am, Tuesday, 25'th Nov 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral...
